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Topical CpG Enhances the Response of Murine
Malignant Melanoma to Dacarbazine
Hossain M. Najar1 and Jan P. Dutz1
Malignant melanoma is a potentially fatal skin cancer that is increasing in incidence. Standard chemoimmu-
notherapy consisting of dacarbazine (DTIC) given with IFN-a has had disappointing results. We describe a
chemoimmunotherapy protocol for cutaneous melanoma that combines the administration of DTIC with the
topical application of CpG oligodinucleotide (ODN). Subcutaneous B16 melanoma tumors in C57BL/6 mice
were treated with intraperitoneal injections of DTIC followed by the topical application of CpG-ODN over the
tumors. This therapeutic approach abrogated the growth of established tumors and significantly enhanced
survival. Topical CpG application was more effective than intratumoral CpG. Cell depletion studies indicated
that the antitumor effect was dependent on both CD4þ and CD8þ cells but not on natural killer (NK) cells.
Tumor-specific cytotoxic T-lymphocyte activity was generated in treated animals and was highest in topically
treated animals. Immunohistochemical analysis revealed that DTIC, but not CpG, enhanced tumor cell
apoptosis. Further, topical CpG induced an expansion of a B220þCD8þ subset of dendritic cells and a subset of
NK1.1þ CD11cþ cells within the tumors. By enhancing both tumor cell death and local immune activation,
DTIC/topical CpG chemoimmunotherapy induced an effective T-cell-dependent host–immune response against
melanoma.
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INTRODUCTION
The incidence of malignant melanoma is increasing. Dacar-
bazine (DTIC) is the standard treatment for metastatic disease.
Unfortunately, the response rate to this single-agent therapy is
limited with little evidence for improved overall survival
(Brown and Kirkwood, 2003). As melanoma is an immuno-
genic tumor, strategies to enhance the immune response to
the tumor have been pursued. IFN-a administration is one
such strategy. Clinical responses to IFN-a may be more
sustained than with standard chemotherapy, but are asso-
ciated with significant toxicity (Brown and Kirkwood, 2003).
Chemoimmunotherapy is a strategy whereby the different
and, perhaps, synergistic mechanisms of action of these
treatments are combined. Again, such combination treat-
ments have not resulted in increased survival for melanoma
patients (Sasse et al., 2007). However, a growing under-
standing of the mechanisms of immunologic tumor rejection
offers hope that more effective therapies can be designed.
Human trials of adoptive T-cell transfer have suggested that
T cells and, particularly, CD8þ cytotoxic T lymphocytes (CTL)
are important effector cells for melanoma rejection (Dudley
and Rosenberg, 2003). Cross-presentation of antigen, where
tissue-specific antigen is processed by antigen-presenting
cells, is one means of priming CD8þ T cells (Heath and
Carbone, 2001). Adjuvants are substances used to enhance
immune responses by inducing efficient antigen presentation
by dendritic cells (DC). Toll-like receptors (TLR) are a family
of 10 microbial pattern recognition receptors that stimulate
DC, and TLR agonists have thus been studied extensively as
potential adjuvants for use in vaccine design and cancer
immunotherapy (Akira et al., 2006). In vitro studies have
determined that TLR3, -7, -8, and -9 enhance the cross-
presentation of antigen and that optimal induction of CD8þ
T-cell responses occurs with TLR7, -8, or -9 stimulation (Datta
et al., 2003; Lore et al., 2003). Studies comparing the efficacy
of TLR7/8 and TLR9 agonists, as vaccine adjuvants in mice,
have shown that superior cell-mediated immune responses
and antibody responses are obtained with TLR9 adjuvants
(Weeratna et al., 2005). As TLR9 is thought to have the
narrowest expression profile among TLRs in humans, this may
allow a safer adjuvancy profile. For example, when non-
human primates are vaccinated with TLR agonists emulsified
with protein antigen, local inflammation was detected at the
site of injection from 2 to 12 weeks with TLR7/8 agonists but
not with TLR9 agonists, despite a similar induction of
functional T-cell memory (Wille-Reece et al., 2006). Thus,
further exploration of the use of TLR9 agonists in chemo-
immunotherapy strategies is warranted.
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Immunostimulatory unmethylated CpG-ODN are potent
adjuvants that signal through TLR9 (Hemmi et al., 2000).
TLR9 agonists have been administered systemically in animal
models and humans to induce antitumor immune responses,
but have so far met with limited clinical success and have had
associated systemic toxicities such as fever and malaise
(Krieg, 2007). We have shown that CpG-ODN may be
applied topically to the skin to induce efficient cross-
presentation of subcutaneous antigen (Najar and Dutz,
2007). Importantly, this proceeds without the systemic
toxicities and cytokine release noted with parenteral admin-
istration.
DTIC induces melanoma cell death (Thallinger et al.,
2003). Dying tumor cells can be engulfed by antigen-
presenting cells leading to the cross-presentation of tumor
antigen (Nowak et al., 2003). We thus proposed that topical
CpG could induce an efficient immune response to malignant
melanoma tumors after DTIC therapy while minimizing
systemic toxicity. Here, we show that the application of
topical CpG after DTIC chemotherapy allows the effective
treatment of established B16 melanoma tumors in mice. This
treatment induces CTL against the tumors, and a dramatic
therapeutic effect that is both CD4þ and CD8þ cell-
dependent. Further, the treatment induces the accumulation
of B220þCD8þ DC within the tumors. This population is
similar to type 1 IFN-producing plasmacytoid DCs that are
known to release IFN-a locally and to promote cross-
presentation of antigens by other DCs (O’Keeffe et al., 2002).
RESULTS
Topical CpG administered in combination with DTIC inhibits
melanoma growth and improves survival
B16 is a murine melanoma cell line that is relatively
immunoresistant (Seliger et al., 2001). DTIC induces mela-
noma cell apoptosis within 6 hours of administration and has
a short half-life in vivo (D’Incan and Souteyrand, 2001). We
reasoned that administration of DTIC, 24 hours before TLR9
agonist administration for the therapy of an established
tumor, would allow for tumor cell apoptosis and decrease
DTIC to levels that do not inhibit T-cell priming. To explore
the potential adjuvant role for topical CpG after DTIC therapy
of melanoma, C57BL6 mice were inoculated with B16
melanoma tumors. Once a tumor mass was well established,
mice were repeatedly treated with DTIC. DTIC is commonly
administered to humans intravenously in 3-week cycles to
limit hematologic toxicity. DTIC was administered to the
mice via intraperitoneal route (80mg kg1) according to a
dosage schedule determined previously (Wack et al., 2001).
Intraperitoneal DTIC administration in rodents has pharma-
cologic effects that are similar to intravenous administration
(Paschke et al., 1993).
DTIC therapy was followed by the application of topical
CpG (Figure 1) to the skin overlying the tumor (termed
epifocal). As topical application of 250 mg of CpG was
superior and less toxic than 50mg subcutaneous CpG for the
induction of immune responses to foreign subcutaneous
antigen (Najar and Dutz, 2007), we also compared the
efficacy of epifocal to intratumoral CpG administration using
similar doses in groups of 10–13 mice. DTIC therapy
modestly decreased tumor growth, as did topical or
intratumoral administration of CpG. However, sequential
administration of DTIC and CpG, either intratumorally or
topically, significantly inhibited tumor growth (Po0.003 and
Po0.001, respectively, compared with untreated). Groups of
mice treated with intratumoral CpG and DTIC demonstrated
a higher tumor volume than topically treated mice (at day 28
from tumor injection mean volume±SE: 1,050±100 vs
290±95mm3, respectively). In a survival analysis, the topical
administration of CpG after DTIC therapy clearly outper-
formed sequential intratumoral administration (Po0.001).
Thus, topical TLR9 agonist therapy after DTIC induces an
effective antitumor response against dermal melanoma.
CpG and DTIC induce a cytotoxic T-cell response against
established dermal melanoma tumors
To determine whether CTL activity was generated against the
B16 tumors by our chemoimmunotherapy regimen, we tested
splenocytes from the treated mice using a standard chromium
release assay. Splenocytes were stimulated once in vitro by
B16 tumor cells and then tested for B16-specific cytotoxicity
(Figure 2). Minimal cytotoxicity was noted in untreated
animals or animals treated with DTIC alone. Significant
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Figure 1. Chemoimmunotherapy with topical or intratumoral CpG and
DTIC controls the growth of established B16 melanomas and improves
survival. Tumor-bearing mice were treated with dacarbazine (DTIC) followed
by CpG application as indicated (either intratumoral—CpG IT or
epicutaneously, overlying the tumor—CpG Epi). This cycle was repeated four
times at 4-day intervals as indicated by arrows. Mice treated with DTIC and
with either epicutaneous (n¼13) or intratumoral CpG (n¼ 10) had less tumor
growth than untreated mice (n¼ 11) (Po0.003 and Po0.001, respectively) or
mice treated with DTIC alone (n¼ 10) (a). Survival analysis (b): mice were
considered terminal when tumors reached 1 cm3 in volume. Using this
outcome measure, mice treated with DTIC and with either topical or IT CpG
survived significantly longer than untreated mice or mice treated with DTIC
alone (Po0.001).
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cytotoxicity was noted against the B16 tumor line but not
against the unrelated thymoma cell line EL4 in animals
treated with DTIC and sequential CpG. Tyrosinase-related
peptide 2 (TRP2) is an immunodominant nonamer melanoma
epitope presented by the Kb MHC molecule (Bloom et al.,
1997). Mice treated with the combination DTIC and CpG
exhibited cytotoxicity to EL4 pulsed with the TRP2 peptide
but not EL4 alone, demonstrating the presence of TRP2-
specific CD8þ CTL within the splenocyte population.
Roughly twofold higher B16 and TRP2-specific cytotoxicity
was reproducibly noted in animals treated with topical CpG
than those treated with intratumoral CpG (41 vs 18% for B16
target responses). This indicates that chemoimmunotherapy
with topical CpG after DTIC induces systemic cellular
cytotoxicity against melanoma and primes immunodominant
epitope-specific CTL against the tumor. Further, topical TLR9
agonist therapy outperforms intratumoral TLR9 agonist
administration in this regard.
DTIC induces tumor apoptosis, whereas topical CpG enhances
B220þCD8þ DC infiltration
TLR9 agonists such as CpG may sensitize tumors to
chemotherapy or may directly induce tumor cell death
(Wang et al., 2006). To evaluate the effect of DTIC on
melanoma cell death in vivo and the potential modifying
effect of topical CpG, tumors of mice treated with DTIC were
compared with tumors treated with combination therapy and
phosphate-buffered saline (PBS) control. Apoptotic cells
within the tumor mass were identified by TUNEL staining,
and the frequencies of these cells were compared among the
groups (Figure 3a and b). DTIC therapy significantly
increased the fraction of apoptotic cells within the tumor
mass (11±3 vs 1.6±0.2%), as did combination therapy with
DTIC and topical CpG (7.8±1.7%). There was little
difference between tumors treated with DTIC alone and
DTIC/CpG. TLR9 agonists are potent stimulators of DC
activation. To determine if local DC cell phenotype modula-
tion occurs at the treated tumor site, the DC cell populations
within the tumors were phenotyped by flow cytometry
(Figure 3c and d). Tumors treated with DTIC and topical
CpG demonstrated the appearance of a distinct
B220þCD8þDEC205CD11cþ population. This population
was induced by topical CpG application, as it appeared in
tumors treated with topical CpG alone (data not shown).
Thus, DTIC induces apoptotic tumor cell death that is not
modified within 48 hours by CpG, and epifocal CpG
application promotes B220þCD8þ DC accumulation within
the tumor. We also asked whether topical CpG application
would promote the infiltration of other cellular subsets. The
generation of IFN-producing killer DC (IKDC) has been
described after the exposure of natural killer (NK) cells to
CpG in vitro (Chan et al., 2006). We find that the fraction of
CD11cþ cells within treated tumors that is NK1.1þ GR-1,
corresponding phenotypically to this population is increased
roughly two- to threefold (Figure 3c and d). This subpopula-
tion is distinct from the B220þCD8þ DC subset described
above as determined by differential CD8 staining (data not
shown).
Both CD4 and CD8 cells participate in the tumor response to
DTIC/CpG therapy
Optimal tumor immunotherapy requires both CD4þ T cell-
and CD8þ T-cell-mediated responses (Schuler-Thurner et al.,
2002). To determine which immune cells participate in
response to DTIC/CpG therapy, we determined the effect of
antibody-mediated depletion of CD4þ cells, CD8þ cells,
and NK receptor-bearing cells upon tumor growth. Groups of
mice were inoculated with tumors and treated with anti-CD4,
anti-CD8, or anti-NK antibodies immediately before the
DTIC/CpG treatment and weekly thereafter. Analysis of tumor
growth (Figure 4a) demonstrated that CD4þ cell depletion
abrogated any inhibition of tumor growth due to DTIC/topical
CpG therapy. An obvious effect of CD8þ cell depletion was
also noted and confirmed in a survival analysis (Figure 4b)
(Po0.002 compared with non-depleted). Unlike melanoma
therapy models in which peritumoral CpG is administered
(Sfondrini et al., 2004), we noted only a very modest
inhibition of protective effect after NK cell depletion using
the NK1.1 antibody.
DISCUSSION
As the molecular and cellular mechanisms of immunologic
tumor rejection have become better understood, specific
stimulation of the host’s immune system to induce melanoma
tumor rejection has been attempted. Approaches to tumor-
specific immunotherapy of melanoma have included che-
moimmunotherapy combining IFN-a or IL-2 with DTIC
therapy, use of tumor lysates and whole tumor vaccines,
tumor-derived peptides, DC-based vaccination protocols,
and adoptive transfer of tumor-specific T cells (Kadison and
Morton, 2003). These approaches have so far met with little
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Figure 2. Chemoimmunotherapy using topical or intratumoral CpG and
DTIC induces melanoma-specific CTL in mice. Splenocytes from mice with
established B16 tumors that were treated with DTIC and with either
intratumoral or epicutaneous CpG, or were left untreated, were re-stimulated
with irradiated B16 cells once in vitro. Chromium release assays were
performed against B16 melanoma or EL4 cells with or without TRP2 peptide.
Mice treated with DTIC and CpG topically mounted CTL responses to both
B16 tumor and TRP2 peptide. The data are expressed as the mean±SD of
triplicate cultures and are representative of three independent experiments.
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success in the clinic or they are complex and labor-intensive
approaches that limit the potential for widespread use.
DTIC induces melanoma cell death by apoptosis. How-
ever, melanoma cells, owing in part to the biological function
of their parent melanocytes, display an intrinsic resistance to
apoptosis (Soengas and Lowe, 2003). Thus, the incidence of
apoptotic melanoma cells is at most 10% as noted here
(Figure 3). This may explain the lack of efficacy of this agent
when used alone (Figure 1). We found no evidence for an
increase in short-term DTIC cytotoxicity toward melanoma
after combination therapy (Figure 3). We reasoned that the
modest DTIC-induced cell death would nevertheless be
sufficient to load DC with tumor antigen in situ and that the
local activation of DC would enhance tumor-specific
immune responses, leading to more effective therapy. Our
results (Figure 1) confirm that the combination of DTIC and
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Figure 3. DTIC induces apoptosis in melanoma tumor-bearing mice and CpG recruits B220þCD8þ dendritic cells. B16 tumor bearing mice (four per group)
were treated with DTIC followed by either CpG topically overlying the tumor mass (DTICþCpG Epi) or saline (DTICþ PBS). Tumors were collected for
immunohistochemical analysis 1 day after treatment. (a) Apoptotic cells were detected using TUNEL assay on tissue sections and cells were enumerated using
DAPI nuclear staining as demonstrated (original magnification  400, scale bar¼ 35mm). (b) Percentage of apoptotic cells were then determined. Data
presented are means±SEM from 10 optical fields per histological section from three mice per group. (c) After four treatment cycles, tumors (three per group)
were removed for flow cytometric analysis. Live cells were gated for CD11cþ cells and plotted for DEC 205 and CD8a (c, upper panel) and were also stained for
pDC (plasmacytoid DC) markers (CD8highB220int) (c, middle panel) and NK cell markers (NK1.1 and Gr-1) (c, lowest panel). (d) The bar graphs show the average
percentage and SEM of CD8highDEC205low, CD8highB220int cells, and NK1.1þ Gr-1 cells among CD11cþ cells recovered from tumors in three separate
experiments. *Po0.004, **Po0.002.
www.jidonline.org 2207
HM Najar and JP Dutz
Chemoimmunotherapy with Topical CpG for Melanoma
local TLR9 stimulation using topical CpG improves the
therapeutic response over either agent used alone.
The potency of TLR9 agonists such as CpG in promoting
CTL responses has led to their experimental use to treat
cancers. Human trials have shown modest responses, and
treatment has been associated with systemic side effects
(Krieg, 2007). Topical CpG administration results in the cross-
priming of subcutaneous antigen and in the rapid activation
of DC within the skin-draining lymph nodes (Najar and Dutz,
2007). We demonstrate here that the topical CpG application
after DTIC treatment of subcutaneous melanomas results in
the generation of CTL to tumor antigen (Figure 2) and in the
accumulation of B220þCD8þ DC within the tumors
(Figure 3). The generation of CTL to a previously defined
B16-dependent tumor antigen is consistent with in situ DC
loading and activation. The B220þCD205CD8þ pheno-
type of accumulating DC (CD11cþ cells) within the tumor is
identical to the phenotype of TLR9-activated type 1 IFN-
producing plasmacytoid DC (O’Keeffe et al., 2002). Such
activated plasmacytoid DC secrete high local levels of IFN-a,
have direct CD4 T-cell-activating function, and induce cross-
presentation of tumor antigen for the activation of CD8 T cells
by conventional DC (Liu, 2005). We have also identified the
accumulation of cells bearing both DC markers (CD11c) and
NK cell markers (NK1.1) within treated tumors. Such cells
have been shown to possess direct cytotoxic activity against
murine melanomas (Taieb et al., 2006). Cell depletion studies
confirm that CD4þ and CD8þ cells (T cells and/or DC), but
not the NK1.1þ cells, critically contribute to the therapeutic
response (Figure 4). This further suggests that systemic
immunity has been obtained. However, the efficacy of this
treatment against systemic (pulmonary) metastases, not
directly treated by the CpG adjuvant, remains to be
determined.
Standard approaches to chemoimmunotherapy for mela-
noma have used the systemic administration of both
chemotherapeutic and immunotherapeutic agents with a
consequent increase in toxic effects without a difference in
survival rate (Sasse et al., 2007). In the clinical setting of
cutaneous melanoma metastases, the multiplicity of tumors
may make them un-resectable or not amenable to isolated
limb perfusion therapy and new therapeutic approaches are
needed. Topical TLR agonist application to promote an
immune response, combined with agents to promote tumor
cell destruction, may provide a novel approach. The topical
TLR7/8 agonist imiquimod induces type 1 IFN responses and
promotes plasmacytoid DC accumulation within murine
melanoma tumors (Palamara et al., 2004). Topical applica-
tion of imiquimod similarly enhances the immune response
to single melanoma lesions destroyed by cryosurgery in mice
(Redondo et al., 2007). Topical imiquimod has recently been
used in attempt to control cutaneous metastatic melanoma in
humans with mixed results (Green et al., 2007; Shistik et al.,
2007).
Parenteral use of TLR9 agonists in advanced human
melanoma may be associated with partial responses (Pa-
shenkov et al., 2006). The systemic use of TLR9 agonists
together with local tumor destruction using cryotherapy
results in increased immune responses and survival in a
murine melanoma model (den Brok et al., 2006). Our results
highlight the potential therapeutic value of topical CpG
application for the management of cutaneous metastases of
malignant melanoma and provide an alternative to the use of
topical imiquimod. In clinical situations where multiple
cutaneous metastases are present, limited tumor cell destruc-
tion by DTIC may be more tolerable than tumor cell
destruction by cryotherapy. As topical CpG in combination
with DTIC induced systemic CTL activity against melanoma
cells, the possibility exists that this treatment may induce
immune responses to widespread metastatic disease. The
relative clinical efficacy of topical TLR7 and TLR9 agonists in
the treatment of cutaneous or widespread metastases by
promoting in situ DC loading and activation and enhancing
the effects of either chemotherapy or cryotherapy for the
treatment of melanoma remains to be determined. Given the
apparent safety and efficacy of topical CpG in the treatment
of cutaneous metastatic melanoma in mice, preliminary
clinical trials of this therapy in humans should be encour-
aged.
MATERIALS AND METHODS
Animals
C57Bl/6 mice (6- to 12-week old) were obtained from Charles River
Laboratories (Wilmington, MA) and housed in a specific pathogen-
free environment. Animal experiments were approved by the Animal
Care Committee of the University of British Columbia.
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Figure 4. CD4þ and CD8þ cells play an active role in tumor regression
after chemoimmunotherapy using topical or intratumoral CpG. Tumor-
bearing mice were treated with anti-NK, anti-CD8, or anti-CD4 antibody
1 day before starting chemoimmunotherapy with DTIC and topical CpG.
Antibody treatment was repeated weekly to ensure the persistent depletion of
the relevant cell population. Mice without DTIC and CpG served as an
additional control. Groups of mice treated with anti-CD8 or anti-CD4
antibody showed no inhibition of tumor growth (a) and lower survival
(Po0.002 for CD8 and Po0.002 for CD4 compared to DTIC/CpG)
(b). Elimination of NK cells had no significant effect on the therapeutic
response to DTIC/CpG treatment.
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Cell lines and reagents
EL4 thymoma and B16-F10 murine melanoma cells were obtained
from the American Type Culture Collection (Manassas, VA) and
cultured in complete medium consisting of RMPI 1640 medium
(Invitrogen, Burlington, ON) supplemented with penicillin G
(100Uml1), streptomycin sulfate (100 mgml1), 5 105 M b-
mercaptoethanol and 10% fetal bovine serum. DTIC was purchased
from Bayer Health Care (Toronto, Canada).
Synthesis of peptides and oligonucleotide
Purified, single-stranded, phosphothioated ODN-1826 (50-TCCAT-
GACGTTCCTGACGTT-30) containing CpG motifs was synthesized
and dissolved in 50ml PBS and DMSO (1:1) and stored at 201C
until use. ODNs were prepared and purified to 480% purity at the
Nucleic Acid and Peptide Synthesis Facility of the University of
British Columbia. TRP2 peptide (SVYDFFVWL: corresponding to
amino acids 180–188 of tyrosinase-related protein 2; Bloom et al.,
1997) was synthesized at the same facility.
Subcutaneous tumors
Tumors were induced by subcutaneous injection of 1 105
melanoma cells in 25 ml PBS on the flank of mice. Treatment was
started 9 days thereafter, when tumors reached an average volume of
4mm3. One treatment cycle consisted of an intraperitoneal injection
of DTIC (80mg kg1) followed at 24 hours by the topical (epifocal)
application of CpG-ODN (250mg in 100ml PBS) over the sub-
cutaneous tumors after tape stripping as described (Najar and Dutz,
2007) or by intratumoral injection of CpG-ODN (50 mg in 25 ml).
Cycles were repeated every 4th day. The tumor volume was scored
every 3 days as half the product of the lengthwidth2. In survival
studies, animals where censored when the tumor measured
1,000mm3.
Flow cytometry
DCs were prepared from tumors removed after four treatment cycles
by digesting the tumor with 1mgml1 collagenase D (Roche, Basel,
Switzerland) supplemented with 40 mgml1 DNase (Boehringer
Mannheim, Mannheim, Germany) in complete medium at 37 1C
for 60minutes. The released cells were collected in complete
medium with 0.1 M EDTA buffer. DCs were enriched using Ficol
(NycoPrep, Oslo, Norway). Cells were incubated on ice with anti-
FcR mAb (2.4G2; American Type Culture Collection (ATCC),
Rockville, MD) to block Fc-binding sites. DCs were stained on ice
for 30minutes with labeled antibodies before FACS analysis on a
FACSCalibur (BD Biosciences San Jose, CA) using CELLQuest
software. Antibodies to CD8a (clone 53-6.7), CD45R/B220 (clone
RA3-6B2), CD11c (clone HL3), NK1.1 (clone PK136), and Gr-1
(clone RB6-8C5) were purchased from Pharmingen (San Diego, CA).
Anti-DEC 205 (clone NLDC-145) was from Cedarlane (Hornby,
Canada).
In vivo depletion of effector cells
Mice (n¼ 5 per group) with palpable tumors were randomly divided
into five groups. Mice were treated with 400mg relevant isotype
antibody (rat IgG1 antibody), anti-NK1.1 (clone PK136; ATCC,
Rockville, MD), anti-CD4 (clone GK1.5), or anti-CD8 (clone 53-
6.72) depleting mAbs given intraperitoneally on day 9 and repeated
weekly. Cell depletion was verified by flow cytometry of peripheral
blood. Antibody treatment resulted in 495% depletion of the
targeted cell population as detected using separate antibodies. Mice
were treated with DTIC and ODN-CpG starting on day 10, and
tumor volumes were scored every 3 days. A control group was left
untreated.
Assessment of in vitro cytotoxic activity
Mice were euthanized 6 days after the last treatment cycle or as
required by tumor growth. A standard 4-hour 51Cr release assay was
performed after in vitro stimulation of splenocytes as described (Najar
and Dutz, 2007). Single-cell suspensions of splenocytes (2 107 per
well) were stimulated in vitro with irradiated (15,000 rad) B16 cells
(2 106 per well) in six-well culture plates in complete medium
supplemented with 50 IUml1 recombinant human IL-2 (Pharmin-
gen). After 5 days culture, effector cells were mixed with 51Cr-labeled
target cells. The target cells B16 and EL-4 cells were pre-pulsed, or
not, with 10mgml1 TRP2 peptide for 90minutes.
Immunohistochemical staining and TUNEL assay
Tumor samples were formalin-fixed and paraffin-embedded. Fluor-
escence-based TUNEL staining of tissue sections was performed
using a kit (Chemicon International, Temecula, CA) according to the
manufacturer’s instructions. Sections were counterstained with DAPI
(Vector Laboratories, Burlingame, CA). Images were captured with a
Zeiss Axioplan fluorescence microscope equipped with a COHO-
CCD camera. Apoptotic cells were counted in 10 fields (selected
stepwise) per section at  400 using one section per animal.
Statistical analysis
Groups of two data sets were compared using two-tailed Student’s
t-tests. Tumor growth curves were compared using Tukey’s honestly
significant difference (HSD) test in a post hoc analysis. Survival
curves were compared using a Kaplan–Mayer log rank analysis.
Results were displayed using Prism 3 (GraphPad, San Diego, CA).
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